<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568656</url>
  </required_header>
  <id_info>
    <org_study_id>CCS1477-01</org_study_id>
    <nct_id>NCT03568656</nct_id>
  </id_info>
  <brief_title>Study to Evaluate CCS1477 in Advanced Tumours</brief_title>
  <official_title>An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellCentric Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellCentric Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477
      in patients with metastatic castration resistant prostate cancer (mCRPC) or advanced solid
      tumours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The RP2D/MTD dose will be determined in Part A. Parts B-E will run in parallel after the completion of Part A.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Treatment-related adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory assessments</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Clinical chemistry and haematology assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>PSA response as defined by Prostate Cancer Clinical Trial Working Group 3 (PCWG-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>CTC response defined as a change from unfavourable (five or more cells) at baseline to favourable (four or fewer cells) post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>malignant soft tissue response rate (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1)
metastatic bone disease status (PCWG-3 bone scan criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression-free survival (rPFS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as the time from start of treatment until objective disease progression as defined by RECIST 1.1 or PCWG-3 or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of CCS1477</measure>
    <time_frame>Up to 16 days after first dose of CCS1477</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration of CCS1477</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CCS1477</measure>
    <time_frame>Up to 16 days after first dose of CCS1477</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of CCS1477</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer</condition>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>CCS1477 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of CCS1477 in patients with mCRPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS1477 Monotherapy - Prostate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCS1477 expansion phase in patients with mCRPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS1477 and Abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCS1477 plus abiraterone acetate in patients with mCRPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS1477 and Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCS1477 plus enzalutamide in patients with mCRPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS1477 Monotherapy - Solid tumours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCS1477 expansion phase in patients with advanced solid tumours with a mutation in p300/CBP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCS1477</intervention_name>
    <description>Capsules, oral</description>
    <arm_group_label>CCS1477 Dose Escalation</arm_group_label>
    <arm_group_label>CCS1477 Monotherapy - Prostate</arm_group_label>
    <arm_group_label>CCS1477 Monotherapy - Solid tumours</arm_group_label>
    <arm_group_label>CCS1477 and Abiraterone</arm_group_label>
    <arm_group_label>CCS1477 and Enzalutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>Abiraterone acetate 500mg tablets plus prednisone/prednisolone</description>
    <arm_group_label>CCS1477 and Abiraterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide 40mg capsules</description>
    <arm_group_label>CCS1477 and Enzalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of consent

          -  ECOG performance status 0-1

          -  Assessable disease (by CT, MRI, bone scan or X-ray)

          -  Adequate organ function

          -  Highly effective contraception measures for duration of study

        Additional inclusion criteria for mCRPC patients only:

          -  Previously received abiraterone and/or enzalutamide (or equivalent anti-androgen), and
             docetaxel (unless ineligible or refused)

          -  Progressive disease documented by one or more of the following:

               -  Biochemical progression defined as at least 2 stepwise increases in a series of
                  any 3 PSA values

               -  Progression as defined by RECIST v1.1 guideline for assessment of malignant soft
                  tissue disease.

               -  Progression defined as two or more new metastatic bone lesions confirmed on bone
                  scan from a previous assessment

          -  PSA at screening ≥2 μg/L

          -  Serum testosterone concentration ≤50 ng/dL

          -  Serum albumin &gt;2.5 g/dL

        Additional inclusion criteria for patients in CCS1477 plus abiraterone combination arm:

          -  Patients must have previously progressed on abiraterone treatment

          -  Patients whose last dose of abiraterone is greater than 6 months prior to start of
             study treatment will receive a 4-week run-in treatment with abiraterone to confirm
             refractoriness to abiraterone treatment

        Additional inclusion criteria for patients in CCS1477 plus enzalutamide combination arm:

          -  Patients must have previously progressed on enzalutamide treatment

          -  Patients whose last dose of enzalutamide is greater than 6 months prior to start of
             study treatment will receive a 4-week run-in treatment with enzalutamide to confirm
             refractoriness to enzalutamide treatment

        Additional inclusion criteria for patients in mutation arm:

          -  Advanced solid tumour with a confirmed mutation in p300/CBP

        Exclusion Criteria:

          -  Intervention with any chemotherapy, investigational agents or other anti-cancer drugs
             within 14 days or 5 half-lives of the first dose

          -  Radiotherapy with a wide field of radiation or to more than 30% of the bone marrow
             within 4 weeks of the first dose of study treatment

          -  Major surgical procedure or significant traumatic injury within 4 weeks of the first
             dose of study treatment

          -  Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken
             within 2 weeks of the first dose of study treatment

          -  Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment

          -  Statins; patients should discontinue statins prior to starting study treatment

          -  Any unresolved reversible toxicities from prior therapy &gt;CTCAE grade 1 at the time of
             starting study treatment

          -  Any evidence of severe or uncontrolled systemic diseases

          -  Any known uncontrolled inter-current illness

          -  QTcF prolongation (&gt; 480 msec).

          -  Primary brain tumours or known or suspected brain metastases.

        Additional exclusion criteria for patients in CCS1477 plus abiraterone combination arm:

          -  Clinically significant cardiac abnormalities

        Additional exclusion criteria for patients in CCS1477 plus enzalutamide combination arm:

          -  History of seizures or other predisposing factors

          -  Use of substrates with a narrow therapeutic index metabolised by CYP2C9 or CYP2C19
             within 2 weeks of the first dose of study treatment

          -  Clinically significant cardiac abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johann de Bono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Clegg, PhD</last_name>
    <phone>+44 7464547447</phone>
    <email>Karen.Clegg@cellcentric.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tomasz Knurowski, MD, MFPM</last_name>
    <phone>+44 1252 842255</phone>
    <email>Tomasz.Knurowski@cellcentric.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Coyle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harriet Walter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Carter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Plummer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann de Bono</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

